Geographical Differences in the Safety and Efficacy of Tofacitinib Versus TNFi: A Post Hoc Analysis of ORAL Surveillance

Abstract Introduction In ORAL Surveillance, incidence rates (IRs) of major adverse cardiovascular events (MACE) and malignancies (excluding non-melanoma skin cancer [NMSC]) in cardiovascular (CV)-risk-enriched patients with rheumatoid arthritis (RA) were numerically greater with tofacitinib in North...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Bogdan Batko, Slawomir Jeka, Piotr Wiland, Agnieszka Zielińska, Maria Stopińska-Polaszewska, Marcin Stajszczyk, Magdalena Kosydar-Piechna, Mary Jane Cadatal, Jose L. Rivas
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Adis, Springer Healthcare 2024-07-01
coleção:	Rheumatology and Therapy
Assuntos:	Antirheumatic agents Cardiovascular diseases Efficacy North America Poland Rheumatoid arthritis
Acesso em linha:	https://doi.org/10.1007/s40744-024-00693-y
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!